N/A N=163 Behavioral Memory Modulation in Nicotine Addiction
Nicotine Use Disorder
Primary: Mean Craving Questionnaire Score, Response to the Novel Cue — 3.43; 3.73; 2.55; 2.88 score on a scale, average of 4 responses
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=124 Boost Study 21270 (Cognition)
Cognitive Function Abnormal
Primary: Task Completion Rate — 66; 57 Percentage of eligible participants
Phase 2 N=100 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Ductal Breast Carcinoma In Situ · Estrogen Receptor Positive
Primary: Change in Ki-67 Labeling Index — -1.0; -4.8 percent positive cells
Phase 2 N=52 Timely Intravenous Magnesium for Asthma in Children
Asthma
Primary: Enrollment — 18; 17; 17 Participants
N/A N=11 Teleoperation Experimental Comparison With Able-bodied Subjects
Amputation; Traumatic, Arm, Upper
Primary: Transfer Success Rate in a Fragile Box and Blocks Task — 67.50; 72.75; 93.46; 95.06 percentage of attempted transfers — p=<0.001
Phase 3 N=1,641 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
Carcinoma, Renal Cell
Primary: Disease-Free Survival (DFS) by BICR - Treatment Part A and B — NA; NA; NA; NA Months — p=0.6676
Phase 4 N=10 Brain and Stress Study
Stress, Psychological · Motivation
Primary: Change in Response Bias During the Probabilistic Reward Task — 0.195; 0.203 Ratio (Response Bias Score) — p=0.856
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
Phase 4 N=53 A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin Amyloid Cardiomyopathy
Primary: Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) — 45; 21; 17; 6 Participants
Phase 4 N=14 A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
Gaucher Disease, Type 3
Primary: Percent Change From Baseline in Spleen Volume Measured by MRI — -51.33 Percent change
Phase 2 N=94 Inulin for Infections in the Intensive Care Unit
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
Phase 2 N=43 Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers
Lung Cancer
Primary: Change From Baseline in Bronchial Dysplasia Index at 12 Months — 1.67; 1.62; 1.55; 1.48 score — p=0.452
N/A N=104 Approach Bias Modification for the Treatment of Cannabis Use Disorder
Cannabis Use Disorder
Primary: Cannabis Approach Bias — -8.43; 4.05; 5.43; -1.36 seconds
N/A N=30 Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
Nocturia · Hypertension · Sleep Disturbance
Primary: Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention — -0.4; 7.3; 3.9 percentage of daytime mean SBP — p=0.65
Phase 2 N=14 Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 2 Participants